首页> 外文OA文献 >Efficacy and Safety of Switching to Dolutegravir/Lamivudine Fixed-Dose 2-Drug Regimen vs Continuing a Tenofovir Alafenamide–Based 3- or 4-Drug Regimen for Maintenance of Virologic Suppression in Adults Living With Human Immunodeficiency Virus Type 1: Phase 3, Randomized, Noninferiority TANGO Study

【2h】

Efficacy and Safety of Switching to Dolutegravir/Lamivudine Fixed-Dose 2-Drug Regimen vs Continuing a Tenofovir Alafenamide–Based 3- or 4-Drug Regimen for Maintenance of Virologic Suppression in Adults Living With Human Immunodeficiency Virus Type 1: Phase 3, Randomized, Noninferiority TANGO Study

机译：切换到DolututeGravir / Lamivudine固定剂量2-药物方案Vs的功效和安全性继续依据基于替诺福尼亚醛酰胺的3-或4-药物方案，用于维持与人类免疫缺陷病毒类型1：第3型，随机化的成人病毒学抑制非流氓探戈研究

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
相似文献
相关主题

著录项

作者
Jean van Wyk; Faïza Ajana; Fiona Bisshop; Stéphane De Wit; Olayemi Osiyemi; Joaquín Portilla Sogorb; Jean-Pierre Routy; Christoph Wyen; Mounir Ait-Khaled; Maria Claudia Nascimento; Keith A Pappa; Ruolan Wang; Jonathan Wright; Allan R Tenorio; Brian Wynne; Michael Aboud; Martin J Gartland; Kimberly Y Smith;
展开▼
作者单位

展开▼
年度 2020
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献

1. Week 96 efficacy and safety results of the phase 3, randomized EMERALD trial to evaluate switching from boosted-protease inhibitors plus emtricitabine/tenofovir disoproxil fumarate regimens to the once daily, single-tablet regimen of darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) in treatment-experienced, virologically-suppressed adults living with HIV-1 [J] . Eron Joseph J., Orkin Chloe, Cunningham Douglas, Antiviral Research . 2019,第期

机译：第9周的疗效和安全结果3阶段，随机祖母绿试验评估从增强蛋白酶抑制剂的切换加上Emtricitabine / Tenofovir Disoproxil富马酸莫霉素治疗达伦韦/钴/ Emtricitabine / Tenofovir Alafenaine的单片体方案（D / C / F / TAF）在治疗经验丰富的病毒学 - 被抑制的成年人与HIV-1一起生活
2. A phase IV randomised, open-label pilot study to evaluate switching from protease-inhibitor based regimen to Bictegravir/Emtricitabine/Tenofovir Alafenamide single tablet regimen in Integrase inhibitor-na?ve, virologically suppressed HIV-1 infected adults harbouring drug resistance mutations (PIBIK study): study protocol for a randomised trial [J] . Collins C. Iwuji, Duncan Churchill, Stephen Bremner, BMC Infectious Diseases . 2020,第1期

机译：IV阶段随机开放标签试验研究，以评估从基于蛋白酶抑制剂的方案转换为Bictegravir / Emtrickabine / Tenofovir alafenainide单片中的整体酶抑制剂-Na've，病毒学抑制的HIV-1感染的成年人患有耐药性突变（Pibik研究）：随机试验的研究方案
3. Efficacy of Rilpivirine-Based Regimens as Switch Therapy From Nevirapine-Based Regimens in Human Immunodeficiency Virus-Infected Patients With Virological Suppression: A Randomized Controlled Trial [J] . Porkaew Petchkum, Somnuek Sungkanuparph, Sasisopin Kiertiburanakul, Open Forum Infectious Diseases . 2019,第4期

机译：Rilpivirine为基础的方案从基于Nevirapine的方案转用疗法在人类免疫缺陷病毒感染的病毒学抑制患者中的疗效：一项随机对照试验
4. Week 48 Results of EMERALD: A Phase 3 Randomized Non-inferiority Study Evaluating the Efficacy and Safety of Switching from Boosted-protease Inhibitors (bPI) Plus Emtricitabine (FTC)/Tenofovir Disoproxil Fumarate (TDF) Regimens to the Once Daily (QD) Single-tablet Regimen (STR) of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) in Virologically Suppressed HIV-1-infected Adults [O] . Chloe Orkin, Jean-Michel Molina, Joel Gallant, 2017

机译：EMERALD的第48周结果：第3阶段的非劣效性研究评估了从加强蛋白酶抑制剂（bPI）加恩曲他滨（FTC）/替诺福韦富马酸替诺福韦酯（TDF）转换为每日一次（QD）的功效和安全性）在病毒学上被抑制感染了HIV-1的成年人中Darunavir / Cobicistat / Emtricitabine / Tenofovir Alafenamide（D / C / F / TAF）的单片治疗方案（STR）
5. Improvement in Metabolic Health Parameters at Week 48 After Switching From a Tenofovir Alafenamide–Based 3- or 4-Drug Regimen to the 2-Drug Regimen of Dolutegravir/Lamivudine [O] . Jean van Wyk, Mounir Ait-Khaled, Jesus Santos, 2021

机译：从替诺福韦醛酰胺的3-或4-药物方案切换到DoluteGravir / Lamivudine的2-药物方案后，将代谢健康参数改善

著录项

相似文献

相关主题

期刊订阅